The Wellness Beyond Cancer Program (wbcp) was launched in 2012, first accepting patients with
INTRODUCTION
In Canada, the incidence of cancer is rising annually, with new cases of cancer reaching an estimated 191,300 in 2014 1 . Advances in treatment and screening have led to an increased number of cancer survivors; 63% 1 of Canadians with cancer are expected to live at least 5 years post-diagnosis.
The unique needs of cancer survivors include screening for disease recurrence, detecting new primary malignancies, managing the late physical effects of cancer treatment, and promoting routine health maintenance [2] [3] [4] . Psychosocial effects of survivorship can include anxiety, depression, and post-traumatic stress disorder 5, 6 . To ensure that survivors have access to coordinated, interdisciplinary, and psychosocial supportive care services during the transition from active treatment to extended survival, health care providers have to be informed on all aspects of survivorship care.
The unique needs of cancer survivors have been an increasing priority in cancer care since the U.S. Institute of Medicine published its report on cancer survivorship in 2005 2 . Their report identified that, after completion of active treatment, cancer patients have important unmet needs; often, they feel lost as they transition back to the care of their primary care provider (pcp), lacking clear guidelines for ongoing care. The Institute of Medicine emphasized that survivorship care should focus on monitoring for the late effects of cancer, surveillance for cancer recurrence, interventions to address illness secondary to cancer and its treatment, and finally, coordination of care between specialists and pcps. By 2006, a series of publications had recognized the paucity of research on cancer survivors 7 ; the needs of survivors were not always identified, and effective guidelines for ongoing care were not always in place 4 . There was consensus that survivorship care in cancer was not well organized, and most clinicians did not have clear and consistent plans for their patients.
In 2013, the American Society of Clinical Oncology (asco) released its assessment of survivorship care in adult cancers 8 . It noted that clear consensus guidelines for providing survivorship care in adults had yet to be established, and asco subsequently made a commitment to develop clinical practice guidelines for survivorship care. In the resulting report, the organization made a number of recommendations, including advocating for a "shared-care model" of delivery (care shared between specialists and pcps), supporting survivorship research, and increasing education about cancer survivorship issues for patients and providers alike.
The delivery model is an important aspect of survivorship care. Historically, patients have been followed by their primary oncologist for an undefined period of time and eventually discharged back to their pcp. A risk-stratified approach is used in the pediatric cancer population: Patients considered low-risk are discharged back to their pcp; moderate-risk patients continue in a shared-care model; and those at high risk continue with their oncologist 9, 10 . That approach has been further refined to utilize a nurse practitioner (np)-led survivor clinic 9, 11 . No model has been shown to be superior 12-14 . In the adult population, models of survivorship care are heterogeneous. In 2015, Halpern et al. 15 published a technical brief covering models of delivery that had been demonstrated in the literature. Their report confirmed the earlier asco findings that survivorship care is not standardized. Further, no evidence that one model is superior to another has been generated. Halpern and colleagues highlighted the need for research into survivorship care models and clinical outcomes for patients. Cancer Care Ontario, the provincial body overseeing cancer care in the province of Ontario, published its clinical guidelines on survivorship care in 2012 14 . The authors of that work found evidence to support delivery of survivorship care either by pcps in the community or by nurses in an institutional setting for survivors of either breast cancer (bca) or colorectal cancer (crc).
Survivorship care plans (scps) are documents intended for patients and pcps alike. The Institute of Medicine recommended scps 2 , which were further described by Earle in 2006 16 . A useful communication tool, the scp ensures that pcps are aware of surveillance requirements and patient needs. The ideal scp has standardized content, with descriptions of disease-site-specific guidelines for recommended follow-up tests, frequency of appointments, late and long-term effects of a patient's cancer and it treatment, and psychosocial concerns; it should simultaneously highlight the need for non-cancer health maintenance.
Criticisms of scps include the substantial amount of time required for their preparation 17 and poor use or uptake by the pcps for whom the plans are intended [17] [18] [19] [20] . Further no funding is specifically dedicated for the preparation of such a document. In a randomized controlled trial involving early-stage bca patients, Grunfeld et al. 21 found scps to be no more effective than a standard discharge visit with respect to patient-reported outcomes and cancer-related distress. That study was criticized on the grounds that a discharge visit is not a standard of care in all countries (and so might not be a broadly generalizable result) and that complex interventions are not as simple to assess as patient-reported outcomes in a mostly well population [22] [23] [24] .
Support for scps has appeared in the literature. A 2011 survey of 30 pcps found that scps were highly valued, increased provider knowledge, and affected care decisions 25 . Those findings were confirmed in a national survey of 1130 oncologists and 1020 pcps about scps 26 . Forsythe et al. 27 found that receipt of a scp improved pcp-perceived coordination of care, communication, and confidence in their knowledge of survivorship issues. In its 2014 expert statement on survivorship care planning, asco recommended use of scps to enhance survivor and pcp education, and provided a scp template.
The Ottawa Hospital is a quaternary care centre with a referral base of approximately 1.5 million patients across Eastern Ontario. In 2011, The Ottawa Hospital Cancer Program (tohcp) embarked on the development of a survivorship program to fit the needs of its patient population. The program was piloted in March 2012 with survivors of crc; survivors of bca were added in February 2013. The Wellness Beyond Cancer Program (wbcp) aims to ensure that referred patients have access to the most appropriate care provider to address their individual needs. In the present report, we detail the development and structure of the wbcp survivorship program and discuss results of the quality review that was undertaken after 1 year of operation for each disease site.
PROGRAM DEVELOPMENT
After a cancer survivorship retreat held in May 2010, tohcp committed to making survivorship a priority. These requirements to enhance survivorship care were identified:
n That all appropriate patients receive detailed information about their cancer diagnosis and treatments received n That all patients be educated on cancer survivorship and the long-term health effects of cancer and cancer treatments n That all patients be aware of their individual medical and psychosocial needs after completion of active cancer treatment n That all patients have access to appropriate follow-up care and to the resources that best meet their needs An interdisciplinary regional steering committee, including patient representatives, was struck. Based on the steering committee's working groups and the growing body of literature, tohcp endeavoured to develop a unique survivorship program combining previously described elements and innovative solutions to satisfy both cancer-specific guidelines and the unique survivorship needs of cancer patients. A call for submissions for survivorship program proposals had been issued by Cancer Care Ontario, and tohcp received a grant to cover the first year of operating costs. Since then, tohcp has funded the program internally. A risk-stratified approach, with options for either institution-based nurse practitioner-led care or community-based pcp care, was chosen. This collaborative project involves medical, radiation, and surgical oncologists; nurses; pcps; and administrative staff at the cancer centre. We believe that the program serves a diverse group of patients and is able to respond to ever-evolving guideline recommendations.
PROGRAM DESCRIPTION
The wbcp consists of a multidisciplinary team of health care providers who work to ensure that, at the end of active cancer treatment, crc and bca patients have access to resources that best meet their individual needs and that the most appropriate health care provider provides survivorship care.
Program Objectives
At the outset of wbcp development, these five objectives to optimize survivorship care at The Ottawa Hospital Cancer Centre were identified:
n Provide cancer survivors, their families, and their pcps with a treatment summary and follow-up plan. n Empower patients to participate in the management of their care and overall well-being once cancer treatment is complete. n Ensure that cancer survivors have access to high-quality post-treatment follow-up care services. n Improve the knowledge of health providers about the needs of cancer survivors and about assessment and management strategies. n Improve cancer program efficiency, and enhance the transition and coordination of care for cancer survivors.
The WBCP Model of Survivorship Care
The wbcp team includes of a program manager, a medical oncology program lead, two nurse practitioners, a registered nurse (rn), and clerical support. All oncology specialists from tohcp can discharge their crc and bca patients to wbcp. The referring oncologist selects the discharge stream based on a clinical assessment of risk of recurrence or complexity of the required follow-up care, or both. The wbcp was developed on a risk-stratification model. Initially, 3 discharge pathways were possible:
n Survivorship care provided exclusively by a pcp n Shared care provided by a wbcp np with a pcp n Continued care by the primary oncologist, with pcpshared care
Patients are referred to one of the wbcp pathways by their oncologist, the goal being that the patient receives the care most appropriate to their individual needs. Most patients referred to the wbcp are eligible to return to their pcp. Those patients are, for the most part, low-risk and without complex care needs. They must, however, have a pcp who is active in their care. In the Ottawa area, approximately 4%-5% of referred patients either lack a pcp or lose their pcp during the journey of their cancer diagnosis and treatment.
Patients referred to the np stream are those who are at higher risk (for example, patients with unresolved toxicity from treatments, or those with significant psychosocial concerns), those who have more complex needs as assessed by the referring oncologist, and those who lack a pcp. Patients in the np stream participate in a shared-care model in which the pcp remains responsible for health maintenance and routine care, and the np offers cancer survivorshipspecific care. The goal for this group is that they eventually transition back to pcp-managed cancer survivorship care once specific needs are addressed.
At program launch, there was a third referral stream in which patients could be referred to the wbcp and continue follow-up with their oncologist. Examples of patients included in that stream are those who were on clinical trial or who had medically complex outstanding needs. Over time, this third stream was determined not to be required, and it was removed from the program in 2013. Figure 1 illustrates the current program model.
Enrolment into the WBCP
At the time of referral, patients complete a needs assessment to self-identify their outstanding physical and psychosocial needs. The completed needs assessment is forwarded, with the program referral, to the wbcp. The wbcp clerk receives the referrals and electronically enters the patient information, including the appropriate referral stream and needs assessment content, into the wbcp database. The clerk then books education sessions and appointments.
All referred patients are invited to attend a 2-hour survivorship education class and are given educational booklets, which include both general and disease-sitespecific information. Topics include understanding the coordination of care beyond cancer treatment, the roles of health professionals in survivor care, signs of cancer return for which to watch, recommendations for cancer prevention and screening, late and long-term effects of cancer, common psychological and emotional needs, and the process for re-entry to the cancer centre when necessary.
Survivorship care plans provide details of a patient's disease, a treatment summary, information about their cancer care team, recommended follow-up surveillance, and outstanding self-identified needs. The scps are created electronically by the wbcp nurse, who pulls relevant information from existing tohcp electronic patient records. The unmet needs self-identified by patients in their needs assessments are automatically populated to the individual care plan. Patients are contacted, and either a wellness appointment is arranged with the rn responsible for the discharge process to the pcp, or the patient is booked into the np clinic for the initial consultation. If the patient is being transitioned to the pcp after the discharge visit, care plans are reviewed with and given to the patient by the wbcp rn, and a discharge letter and copy of the care plan are sent to the pcp. Appointments with the wbcp rn last approximately 30 minutes. At this visit, the scp is reviewed in detail, and symptom management to help address the patient's outstanding self-identified needs is provided. For patients entering the np stream, the initial appointment is similar to a new consultation by a physician; it lasts 30-45 minutes. The frequency with which a patient sees the np in follow-up depends on the complexity of that patient's medical needs. Patients in the np stream will be discharged back to their pcp (if one is available) as soon as their survivorship needs allow. The timing is unique for each patient, and there is no limit to the number of appointments or the length of time a patient spends with their np survivorship care provider.
Hormone Reassessment Referral System
A significant proportion of women with early-stage bca are hormone receptor-positive. The standard of care mandates a discussion concerning an adjuvant program incorporating an aromatase inhibitor for postmenopausal women and extended adjuvant therapy for suitable higher-risk individuals. In the past, such women would then have been followed at our centre for up to 10 years. Cancer Care Ontario endorses the discharge of bca patients back to pcp or institution-based nurse-led care while those patients are still on hormonal treatment 16 .
We developed a "hormone reassessment referral" for such patients as they transition from their specialist to their pcp. The referral is a formal way to track patients who will require follow-up for more than 1 year in the future to address potential changes to the hormonal therapy, something that would normally require a new referral from an outside physician in our health care system. At the time of discharge, the referring oncologist requests a hormone reassessment at a specified month and year. That date is captured electronically and logged within the cancer centre database; the patient is then appropriately booked for a future reassessment with their primary oncologist. To be respectful of the wait times for a primary consultation, reassessment appointments are restricted to no more than 2 per week per oncologist. Although this unique process was developed for bca, the concept could, where indicated, be broadened to other cancer disease sites in consideration of future therapeutic innovations.
Rapid Re-entry Process
An integral part of the wbcp design is our rapid re-entry process for discharged patients with either suspected or documented recurrence or new primary cancers. The pcps have access to the wbcp-dedicated telephone number for consultation purposes. That number reaches the wbcp rn, who triages and expedites a rapid re-entry referral as necessary. This process minimizes anxiety about disease recurrence for patients and pcps alike.
Implementation
The program was launched in 2012 for crc patients. Because the region served by tohcp is large, we travelled to various communities, holding meetings with stakeholders (especially pcps and nps) to educate them about the program and its resources. Information was disseminated throughout the tohcp to educate clinicians of its availability. Formal presentations were made to oncologists treating patients with bca and crc. As with any program, the early adopters helped the wbcp gain general acceptance. The program met a need to help formalize the discharge process from a busy cancer centre trying to keep up with the demand to see new patients, and so it was well received by many. Although some oncologists initially resisted participating, the program has, over time, become an integral part of the standard of care for all providers for their crc and bca patients. Ongoing communication and program updates have been provided by the wbcp team, and feedback has been invited at every stage of development.
As the program developed, experience and feedback led to changes. The education component was condensed from two survivorship classes into a single disease-specific class. In addition, in the initial risk stratification, a small number of patients, primarily those on clinical trial, stayed with their oncologist. Subsequently, mechanisms to ensure adherence with clinical trials were implemented, and this third referral option was removed. In the first phase of the program, all treating specialists had been required to agree whether a patient was ready for discharge from the cancer program. Because that requirement caused some disagreement, an oncologist can now refer a patient to the wbcp, and their oncology colleagues might choose to personally continue follow-up care until they are also confident to discharge to the pcp.
PROGRAM EVALUATION Methods
One year after referral to the wbcp, patients and their pcps were mailed surveys to assess program satisfaction. A survey was also distributed to the members of the tohcp team. We obtained institutional research ethics board approval for quality assurance projects relating to the wbcp. Data were compiled from the surveys that were returned by mail. Survey responses were anonymous, no patient-or pcp-identifying information was collected as part of the quality review. An electronic survey was also sent to tohcp staff inquiring about their experiences with the program and their views on the utility of the program. Questions for that survey were asked on an agree/disagree/ not applicable scale.
The wbcp team designed the surveys with questions structured to obtain feedback and to determine whether the program is meeting its objectives. The patient survey asked questions concerning knowledge of care received, care plans, and satisfaction. The pcp survey inquired about content and satisfaction with program resources and support. Most questions were scored 1-5 based on level of agreement with each statement (from 1, strongly disagree, to 5, strongly agree). In other questions, patients were asked to pick their top 2 most useful elements of the program and to indicate any and all late effects of cancer they might have been experiencing. Patients and providers both had the opportunity to provide comments and feedback about the program experience. Appendix A presents the patient and provider surveys.
Results
Each year, tohcp sees more than 6000 new referrals. At time of program launch, estimates placed the number of eligible patients at 4000 with bca and 550 with crc. From March 2012 to November 2014, 2630 patients were referred to the wbcp: 809 with crc, and 1821 with bca. Most referred patients have been directed through the pcp stream (n = 1657), followed by the np stream (n = 956). A few patients (n = 17) continued to be followed by their primary oncologist. Of all referred patients, 53 have returned to the tohcp: 26 from the pcp stream, and 27 from the np stream. Reasons for re-entry were disease recurrence (n = 49), a new primary (n = 3), and planned hormonal therapy reassessment (n = 1).
Surveys were mailed to 126 crc and 163 bca patients 1 year after their discharge from the program to the pcp stream. Of the 126 crc patients, 56 (44%) responded, and of the 163 bca patients, 73 responded (45%). Table i presents the results of the patient surveys. Almost all questions received a median score of 4 (range: 1-5), which correlates with the "strongly agree" response to the questions posed about satisfaction with the program. The crc patients identified ongoing concerns with bowel function, sexual dysfunction, peripheral neuropathy, and fatigue. The bca patients identified a greater number of issues 1 year after discharge: menopausal symptoms, weight gain, joint pain, fatigue, memory concerns, anxiety or depression, lymphedema, and sexual dysfunction.
Surveys were also sent to 261 pcps of crc patients and 151 pcps of bca patients. Responses were received from 70 pcps of crc patients (27%) and from 43 pcps of bca patients (28%). Table ii presents the results of the pcp surveys. Survey scoring by the pcps was similar whether they were treating bca or crc patients. Median scores of 4 (range: 2-5) were obtained for questions concerning comprehension of care plans, comfort in ordering tests, and pcp understanding of program operations. Overall, 79% of crc pcps and 85% of bca pcps answered yes when asked if the wbcp has assisted them in coordination of care for their patients. Feedback was collected from the pcps as well. For reporting purposes, the comments were categorized and are shown at the bottom of Table ii. The comments most commonly gave positive feedback (crc 38%, bca 35%); requests for increased communications from the wbcp was the next most common feedback (crc 18%, bca 12%). Only 4% of crc pcps and 6% of bca pcps felt that the wbcp led to worse patient care.
The opinion of tohcp staff is also an important component of measuring the success of the wbcp. A survey was sent to tohcp staff 1 year into operations. Responses to the questions (with agree/disagree answers) were received from 10 staff members in various disciplines (Table iii) .
DISCUSSION
Although the incidence of cancer continues to rise, advances in diagnosis and treatment have led to exponential growth in the number of cancer survivors being followed in cancer centres. At our institution, implementation of the wbcp was critical to ensuring that we could safely transition patients back to their pcps while ongoing cancer-specific health care needs were being met after completion of acute treatment. It was also necessary to ensure best practice and to meet tohcp's target for newly diagnosed cancer patients to be seen in the cancer centre within 2 weeks of referral where possible. As developed for tohcp, the wbcp combines previously reported models of care, including risk stratification, shared-care models, and the use of scps. Despite the criticisms scps receive, our program uses them because we feel that the clear communication they offer is valued by patients and providers alike, and our survey responses seem to support that perception of their value. Nevertheless, when asked for feedback, almost 20% of pcps still felt that more communication would be helpful.
Through experience and receipt of stakeholder feedback, the wbcp has been enhanced by changes such as streamlining the education classes and removing the stream in which patients stayed with their treating oncologist. More enhancements will be required as research emerges. Recent data suggest that extended adjuvant therapy is the standard of care for many women with early-stage hormone receptor-positive bca. The long durations of care that result have presented challenges with respect to being able to discharge patients with specific and unique recommendations. We have therefore developed a "hormone reassessment" system that allows for bca patients to be discharged to their pcp for a defined period, with a planned re-consult with their oncologist being booked in advance.
After 1 year in the program, patients and pcps alike were sent surveys in the mail. Median satisfaction scores Answer scale of 1-5 (1 = strongly disagree; 2 = disagree; 3 = neither disagree or agree; 4 = agree 5 = strongly agree). on our 5-point scale were consistently high, regardless of the respondent type (patient or pcp) or the disease site (crc or bca). Based on direct feedback, the results show that there is room to grow in areas of program communication, especially with pcps. Because of the requirement that patients and their pcps be 1 year out from enrolment, the number of patients surveyed was small relative to the number currently enrolled in the program. Although more than 3000 patients have now been referred to the wbcp, early referrals-regardless of disease site-were slow, which limited the number of patients selected to receive a survey. The response rate (45% of patients, 28% of pcps) was lower than we would have liked. Survey results did not control for differences in time since the cancer diagnosis or active treatment. The range of variance is potentially wide; some patients might have been discharged at 6 months after treatment; others, at more than 5 years after. Similarly, the surveys did not control for stage of disease. Either of those factors might affect satisfaction with the program from the perspective of either the patient or the pcp and thus limit our ability to draw firm conclusions about the levels of satisfaction that patients and pcps are experiencing. We assumed that those who had strongly negative feelings would respond to the survey and would therefore skew the results negatively. If anything, the positive response suggests that patients and providers are more satisfied than the survey results would indicate. For future evaluations, we are considering other methods such as direct contact for patient surveys and use of e-mail for pcps. We also have to include the np stream in our next round of quality assurance, because that stream was not part of the present study. Currently, the clinical outcomes needed to evaluate the safety of our survivorship program are missing. We felt that not enough time has passed to draw any conclusions about clinical outcomes. It is encouraging to note that only 2% of patients have been referred back to tohcp for reasons of either disease recurrence or a new primary cancer. We are currently tracking all patients who are referred back to determine whether early discharge was a contributing factor in their re-referral. To date, no reports of adverse cancer-specific outcomes have been received; however, we will continue to monitor patients for a future safety analysis.
CONCLUSIONS
The wbcp ensures that the most appropriate provider is selected for all crc and bca patients transitioning from active cancer treatment. Early data and stakeholder feedback demonstrate that the wbcp has improved the programming offered to cancer survivors and has allowed crc and bca patients to move beyond being a cancer patient to being a cancer survivor. To ensure the ongoing success and sustainability of this much-needed program, we are endeavouring to undertake a full program review, including, as already mentioned, safety data relating to patient outcomes. (e) The program has improved the co-ordination of follow-up care.
(f) I know who to contact should I have any additional questions.
(g) I know the process for re-entry back to the WBCP, if required.
2. Please share any benefits you feel the program has provided.
3. Do you feel the WBCP has assisted you in co-ordinating care for your patients?
Yes I know which type of surgery I had for my cancer.
I know which type of chemotherapy medication I received for my cancer.
I know which hormonal therapy I am receiving for my cancer.
I know which radiation therapy I received for my cancer.
I know when and how often I need to get follow-up visits for my cancer.
I know how to schedule follow-up visits with my family doctor or nurse practitioner.
I know the common and significant health risks that I may face due to my cancer and cancer treatments.
I know what symptoms to report to my with my family doctor or nurse practitioner.
I know my family doctor or nurse practitioner's contact information.
I know where to get professional psychological, social support, if needed.
I know where to get additional help outside the hospital (for example, help with daily activities, finances, self-help or support-groups, rehabilitation services). 
Extremely satisfied
The overall support I received
The overall care I received
The overall quality of information I was provided 9. As part of your care plan, the follow-up tests below may have been recommended. Please tell us more about the tests you have had. I know which type of chemotherapy medication I received for my cancer.
I know what symptoms to report to my family doctor or nurse practitioner.
I know where to get professional psychological and social support, if needed.
I know where to get additional help outside the hospital (for example, help with daily activities, finances, self-help or support groups, rehabilitation services). 
The overall quality of information I was provided 9. As part of your care plan, the follow-up tests below may have been recommended. Please tell us more about the tests you have had. 
